AU784359B2 - Compositions and methods for inhibiting endothelial cell proliferation - Google Patents

Compositions and methods for inhibiting endothelial cell proliferation Download PDF

Info

Publication number
AU784359B2
AU784359B2 AU30748/01A AU3074801A AU784359B2 AU 784359 B2 AU784359 B2 AU 784359B2 AU 30748/01 A AU30748/01 A AU 30748/01A AU 3074801 A AU3074801 A AU 3074801A AU 784359 B2 AU784359 B2 AU 784359B2
Authority
AU
Australia
Prior art keywords
hgf
angiogenesis
cells
fragments
protein
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU30748/01A
Other languages
English (en)
Other versions
AU3074801A (en
Inventor
Clara Dey
Hong Liang
Kim Lee Sim
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Casi Pharmaceuticals Inc
Original Assignee
Entremed Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Entremed Inc filed Critical Entremed Inc
Publication of AU3074801A publication Critical patent/AU3074801A/en
Application granted granted Critical
Publication of AU784359B2 publication Critical patent/AU784359B2/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1833—Hepatocyte growth factor; Scatter factor; Tumor cytotoxic factor II
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/12—Keratolytics, e.g. wart or anti-corn preparations
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Dermatology (AREA)
  • Rheumatology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Vascular Medicine (AREA)
  • Diabetes (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Hematology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Oncology (AREA)
  • Urology & Nephrology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Communicable Diseases (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
AU30748/01A 1999-12-15 2000-12-15 Compositions and methods for inhibiting endothelial cell proliferation Ceased AU784359B2 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US17100799P 1999-12-15 1999-12-15
US60/171007 1999-12-15
US19356600P 2000-03-31 2000-03-31
US60/193566 2000-03-31
PCT/US2000/034039 WO2001044294A2 (en) 1999-12-15 2000-12-15 Compositions and methods for inhibiting endothelial cell proliferation

Publications (2)

Publication Number Publication Date
AU3074801A AU3074801A (en) 2001-06-25
AU784359B2 true AU784359B2 (en) 2006-03-16

Family

ID=26866643

Family Applications (1)

Application Number Title Priority Date Filing Date
AU30748/01A Ceased AU784359B2 (en) 1999-12-15 2000-12-15 Compositions and methods for inhibiting endothelial cell proliferation

Country Status (5)

Country Link
EP (1) EP1242451A2 (ja)
JP (1) JP2003517007A (ja)
AU (1) AU784359B2 (ja)
CA (1) CA2394167A1 (ja)
WO (1) WO2001044294A2 (ja)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7601365B2 (en) * 2000-08-28 2009-10-13 Damavand Wound, AB Synergetic effects of HGF and antibacterial treatment
AU8591901A (en) 2000-09-05 2002-03-22 Karolinska Innovations Ab Materials and methods relating to endothelial cell growth inhibitors
WO2003002610A1 (en) * 2001-06-29 2003-01-09 Incyte Genomics, Inc. Extracellular messengers
FR2831540B1 (fr) * 2001-10-31 2004-07-09 Inst Vaisseaux Et Du Sang Peptide isole du facteur de croissance hepatocytaire et ses variants, procede de preparation et utilisation en therapeutique en tant qu'agents antiangiogeniques
AU2003270118A1 (en) * 2002-08-30 2004-03-19 F. Hoffmann-La Roche Ag Scatter factor/hepatocyte growth factor antagonist nk4 for the treatment of glioma
JP2004123650A (ja) * 2002-10-04 2004-04-22 Medgel Corp Ｎｋ４を含有する徐放性製剤
DK1687636T3 (da) * 2003-09-29 2009-05-11 Peas Inst Ab Hurtig bestemmelse af forskellige former for hepatocytvækstfaktor (HGF) i legemsvæsker
EP1863519B1 (en) 2005-03-31 2013-09-25 The General Hospital Corporation Modulating hgf/hgfr activity for treating lymphodema
JP5137818B2 (ja) * 2006-03-20 2013-02-06 生化学工業株式会社 関節リウマチの処置剤
JP5530635B2 (ja) * 2007-02-14 2014-06-25 独立行政法人科学技術振興機構 腸管癒着抑制剤
JP2009091339A (ja) * 2007-10-12 2009-04-30 Seikagaku Kogyo Co Ltd 関節リウマチの処置剤
CN102336812B (zh) * 2010-07-28 2015-12-02 上海市第一人民医院 一种具有抑制血管生成活性的多肽

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0890361A1 (en) * 1995-10-24 1999-01-13 NAKAMURA, Toshikazu Antitumor agent

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69133349T2 (de) * 1990-09-14 2004-10-07 Us Health Ein nicht-mitogener kompetitiver hgf-antagonist
WO1997023500A1 (en) * 1995-12-13 1997-07-03 The Children's Medical Center Corporation Endothelial cell proliferation inhibitor and method of use
US5801146A (en) * 1996-05-03 1998-09-01 Abbott Laboratories Compound and method for inhibiting angiogenesis
US6107473A (en) * 1997-10-01 2000-08-22 Smithkline Beecham Corporation Kringle-related clone HTHBZ47
GB9815505D0 (en) * 1998-07-16 1998-09-16 Adprotech Plc Polypeptide derivatives
JP2002535372A (ja) * 1999-01-28 2002-10-22 ザ チルドレンズ メディカル センター コーポレイション プラスミノーゲンクリングル４領域フラグメントおよび利用法
AU4445100A (en) * 1999-04-14 2000-11-14 Karolinska Innovations Ab Kringle domains of plasminogen, capable of modulating angiogenesis in vivo

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0890361A1 (en) * 1995-10-24 1999-01-13 NAKAMURA, Toshikazu Antitumor agent

Also Published As

Publication number Publication date
AU3074801A (en) 2001-06-25
WO2001044294A2 (en) 2001-06-21
CA2394167A1 (en) 2001-06-21
WO2001044294A3 (en) 2002-02-07
JP2003517007A (ja) 2003-05-20
EP1242451A2 (en) 2002-09-25

Similar Documents

Publication Publication Date Title
US6413513B1 (en) Compositions and methods for inhibiting endothelial cell proliferation and regulating angiogenesis using cancer markers
US7485439B2 (en) Nucleic acids encoding plasminogen fragments and methods of use
KR100336452B1 (ko) 앤지오스타틴및맥관형성억제를위한이의사용방법
CA2219081C (en) Angiostatin fragments and aggregate angiostatin and methods of use
AU784359B2 (en) Compositions and methods for inhibiting endothelial cell proliferation
JP2001518304A (ja) アンギオスタチン成分を含む融合タンパク質及び抗腫瘍療法におけるその使用
CA2240296C (en) Endothelial cell proliferation inhibitor and method of use
US20040253226A1 (en) Compositions and methods for inhibiting endothelial cell proliferation and regulating angiogenesis using serine proteases
US20040121945A1 (en) Compositions and methods for inhibiting endothelial cell proliferation
WO2000061179A1 (en) Kringle domains of plasminogen, capable of modulating angiogenesis in vivo
CA2360690A1 (en) Plasminogen kringle 4 region fragments and methods of use
US7241446B2 (en) Methods for modulating angiogenesis via VEGF
CA2361334C (en) Deglycosylated kringle 1-3 region fragments of plasminogen and methods of use
EP1268798B1 (en) Anti-angiogenic properties of vascostatin and fragments or variants thereof
AU2001287274B2 (en) Anti-angiogenic and anti-tumor properties of vascostatin and other nidogen domains
US7629146B2 (en) Truncated 24kDa basic fibroblast growth factor
KR19990008029A (ko) 안기오스타틴 단편과 안기오스타틴 응집체 및 이의 이용방법
AU2001287274A1 (en) Anti-angiogenic and anti-tumor properties of vascostatin and other nidogen domains
MXPA99011041A (en) Angiostatin fragments and method of use
AU4440402A (en) Angiostatin fragments and method of use